ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($1.59) per share and revenue of $3.11 million for the quarter.
ABIVAX Société Anonyme Stock Performance
Shares of ABVX traded up $0.02 during trading hours on Friday, reaching $6.04. 7,279 shares of the company's stock traded hands, compared to its average volume of 141,677. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $14.71. The firm's 50 day simple moving average is $6.25 and its 200-day simple moving average is $6.98.
Hedge Funds Weigh In On ABIVAX Société Anonyme
Large investors have recently modified their holdings of the company. Woodline Partners LP grew its position in ABIVAX Société Anonyme by 319.5% during the first quarter. Woodline Partners LP now owns 201,924 shares of the company's stock valued at $1,262,000 after acquiring an additional 153,788 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of ABIVAX Société Anonyme by 6.0% in the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company's stock worth $6,171,000 after acquiring an additional 56,235 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of ABIVAX Société Anonyme by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have issued reports on ABVX. Morgan Stanley reiterated an "equal weight" rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Wednesday, April 30th.
Check Out Our Latest Analysis on ABVX
ABIVAX Société Anonyme Company Profile
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Recommended Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
